Compared side by side

Semaglutide vs ecnoglutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are weekly GLP-1 receptor agonists on the same receptor; ecnoglutide, from Sciwind Biosciences, carries one amino-acid change built to favour the receptor’s cAMP signal (“cAMP-biased”), plus a fatty-acid chain for a long half-life. Semaglutide is FDA-approved, as Ozempic and Wegovy; ecnoglutide was approved in China in 2026 for weight management and type 2 diabetes and isn’t FDA-approved. Semaglutide averaged about 15% weight loss at 68 weeks in its main trial, and ecnoglutide’s 2.4 mg about 13% at 40 weeks and about 15% at 48 weeks in its phase 3 obesity trial.

Side by side

ComparedSemaglutideEcnoglutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asOzempic, WegovyXW003, XW004, VRB-101, Ecno
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased".
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.Once-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.Appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.Research range: 0.6–2.4 mg, starting dose 0.3 mg. Studied in research — not a recommendation.
How oftenWeekly SubQWeekly
Half-life~1 week (FDA label)~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026)
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.Used continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskDecreased appetite, diarrhea, nausea, abdominal bloating, weakness

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or ecnoglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Ecnoglutide

  • Day 1–28 · 0.3 mg A low first month
  • Day 29–56 · 0.6 mg Doubling to 0.6 mg
  • Day 57–336 · 1.2 mg The lowest weight-loss dose
  • Day 85–336 · 1.8 mg The middle dose
  • Day 85–336 · 2.4 mg The top dose
  • Day 337+ A long-term medicine, not a course

Every card for ecnoglutide, with its sources

Questions people ask

How long do semaglutide and ecnoglutide last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).

How often are semaglutide and ecnoglutide taken?

Semaglutide: weekly SubQ. Route: SubQ injection. Ecnoglutide: weekly. Route: SubQ injection.

How are semaglutide and ecnoglutide dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for ecnoglutide is 0.6–2.4 mg, with a 0.3 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of semaglutide and ecnoglutide?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For ecnoglutide: decreased appetite, diarrhea, nausea, abdominal bloating, weakness.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or ecnoglutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo